Press release
Trial Attorney Says Merck is 'Step Closer to Accountability' as VIOXX Trial Continues
Attorney Mark Lanier: 'Merck Can't Turn a Loss Into a Win Just By Saying It's So'ATLANTIC CITY, N.J., March 7 /PRNewswire/ -- A jury on Friday in New Jersey Superior Court imposed a serious and strong verdict against Merck & Co., finding that the manufacturer of VIOXX(R) withheld information and made misrepresentations to doctors and to the public about the heart attack risks associated with the drug.
The jury unanimously confirmed four counts of fraud in the marketing of VIOXX(R) making Merck liable for millions of dollars in damages, attorney fees and expenses. Also, the jury unanimously found that Merck failed to adequately warn patient Mike Humeston about the dangers posed by Vioxx. In doing so, jurors reversed a 2005 finding on behalf of Merck against the Humeston family.
Mark Lanier, lead attorney for the victims of VIOXX(R) says, "Since the verdict, spinmeisters on behalf of Merck have attempted to characterize this significant defeat as somehow a victory." Merck received one positive finding out of six from jurors who found that Merck provided adequate warning before the fatal heart attack of Brian Hermans. According to Lanier, "The practical impact of that finding is minimal. It means that Brian's family can't pursue damages that would have been capped at $350,000. While that represents a substantial amount of money, it is
dwarfed by the financial liability Merck faces for defrauding the public and the medical community."
In phase two of the current trial, jurors will determine whether VIOXX(R) was a primary cause of Mr. Humeston's heart attack. Jurors will also determine damages for both plaintiffs under New Jersey's consumer fraud laws.
Merck is expected to appeal the verdicts in both the Hermans and Humeston cases, rather than pay millions of dollars in damages and fees. Lanier and The Lanier Law Firm have faced Merck on behalf of five separate
plaintiffs. Merck is appealing the result in each case.
VIOXX(R) was approved by the Food and Drug Administration in May 1999 for the relief of osteoarthritis and menstrual pain, and later for treatment of the signs and symptoms of rheumatoid arthritis. Merck pulled
the drug from pharmacy shelves in September 2004 after a study linked it to an increased risk of heart attacks. Merck, the No. 4 drug maker in the country, now faces nearly 27,000 suits over the drug.
Mr. Lanier won the first-ever VIOXX(R) trial in the summer of 2005, when an Angleton, Texas, jury awarded his client $253.5 million. In that case, jurors found Merck liable in the 2001 death of Robert Ernst, a physically fit triathlete who died after taking the drug for eight months.
With offices in Houston and New York, The Lanier Law Firm is committed to addressing client concerns with effective and often untraditional solutions. The firm is composed of outstanding trial attorneys with decades of experience handling cases involving pharmaceutical liability, asbestos exposure, business fraud, serious personal injuries, product liability, and toxic exposure. For more information, visit www.lanierlawfirm.com.
The Lanier Law Firm
www.lanierlawfirm.com
Houston Law Office
6810 FM 1960 West
Houston, Texas 77069
(713) 659-5200
(713) 659-2204 β Fax
New York Law Office
Lanier Law Firm, PLLC
Tower 56
126 East 56th Street, 6th Floor
New York, NY 10022
(212) 421-2800
(212) 421-2878 β Fax
Press contact:
Mike Androvett
800-559-4534
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Trial Attorney Says Merck is 'Step Closer to Accountability' as VIOXX Trial Continues here
News-ID: 16676 • Views: β¦
More Releases for Merck
Swine Fever Vaccine Market Detailed in New Research Report By 2032 | Merck & Co. β¦
π ππ°π’π§π π
ππ―ππ« πππππ’π§π πππ«π€ππ ππ¨ π π«π¨π° ππ π ππππ π¨π π.π% (ππππ - ππππ)
The Swine Fever Vaccine Market Report is the result of extensive research and analysis conducted by our team of experienced market researchers through -
Β» 70% efforts of Primary Research
Β» 15% efforts of Secondary Research
Β» 15% efforts from the subscription to Paid database providing industry overview, macro and micro economics factors, and financials of private limited companies
πβ¦
Women's Health Market Industry Growth Report to 2031 Merck KGaA, Merck & Co, Fer β¦
[New York, December 2024] Women's Health encompasses a broad spectrum of medical and wellness services tailored to address the unique health needs of women across all life stages. This crucial sub-market of healthcare highlights the necessity for specialized treatments, preventive care, and holistic wellness approaches that resonate with today's female patients. Women's Health isn't just a niche sector; it represents a burgeoning field within healthcare, mirrored by an increasing globalβ¦
Laboratory Syringe Market Size, Growing Demand to 2036 GESERCO, Merck Millipore, β¦
A laboratory syringe is a precise instrument commonly used for the accurate measurement and transfer of liquids or gases in scientific experiments. Unlike standard medical syringes, laboratory syringes are often made of materials such as glass or high-quality plastic to withstand chemical reactions and offer greater clarity for observing contents. They come in a range of sizes, from as small as 1 mL to over 100 mL, and are oftenβ¦
Leuprorelin Acetate Market Analysis By Top Keyplayers - Merck, Takeda, MediGene, β¦
The "Leuprorelin Acetate Market" is expected to reach USD xx.x billion by 2031, indicating a compound annual growth rate (CAGR) of xx.x percent from 2024 to 2031. The market was valued at USD xx.x billion In 2023.
Growing Demand and Growth Potential in the Global Leuprorelin Acetate Market, 2024-2031
Verified Market Research's most recent report, "Leuprorelin Acetate Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2023-2030," provides an in-depthβ¦
Avelumab Market Analysis By Top Key Players - Merck, Pfizer, Merck
The "Avelumab Market" is expected to reach USD xx.x billion by 2031, indicating a compound annual growth rate (CAGR) of xx.x percent from 2024 to 2031. The market was valued at USD xx.x billion In 2023.
Growing Demand and Growth Potential in the Global Avelumab Market, 2024-2031
Verified Market Research's most recent report, "Avelumab Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2023-2030," provides an in-depth examination of theβ¦
Nanobodies Market to See Booming Growth 2021-2028 | Novo Nordisk A/S, Merck & Co β¦
πππ§π¨ππ¨ππ’ππ¬ πππ«π€ππ top level players are analyzed in report based on current and future development status, and Nanobodies market estimations from 2021 to 2028 in terms of revenue and volume. This report provides strategic recommendations consulted by the industrial experts including market share worldwide, future outlook, cost profit structure, supply, raw materials, labour cost, manufacturing expenses, latest market trends, demands, ROI.
The Nanobodies market report analyse the manufacturing cost of theβ¦